Envestnet Asset Management Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Asset Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,138 shares of the biopharmaceutical company’s stock after acquiring an additional 10,060 shares during the period. Envestnet Asset Management Inc. owned 0.08% of Regeneron Pharmaceuticals worth $64,921,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Pamalican Asset Management Ltd purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $4,915,000. Intact Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Rhenman & Partners Asset Management AB grew its position in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after acquiring an additional 4,457 shares in the last quarter. Finally, Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $576.72 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The stock has a market cap of $63.05 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 2.34 and a beta of 0.44. The business has a 50 day moving average of $665.21 and a 200-day moving average of $762.01. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.